Prediction of MMSE Scores for Cognitive Impairment

November 22, 2024 updated by: Blekinge Institute of Technology

Prediction of MMSE Scores for Cognitive Impairment: A Machine Learning Analysis of Oral Health and Demographic Data in Individuals Over 60 Years of Age

This study aims to explore the potential of using machine learning (ML) algorithms to predict cognitive status, specifically MMSE scores, based on oral health and demographic data. The objective is to evaluate the effectiveness of various ML models and identify the most relevant oral health indicators for predicting MMSE scores of 30 (normal cognition) or ≤26 (cognitive impairment) in individuals aged 60 and above.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

This cross-sectional study utilizes oral health and demographic data from two existing cohort studies: the European collaborative study Support Monitoring and Reminder Technology for Mild Dementia (SMART4MD) and the Swedish National Study on Aging and Care (SNAC-B). Participants aged 60 years or older will be included in the analysis. The data will be used to develop and evaluate machine learning models for predicting cognitive status.

Objectives:

  1. Primary Objective: To assess the potential of oral health parameters for binary classification of MMSE scores (30 vs. ≤26).
  2. Secondary Objective: To identify the most influential oral health parameters contributing to cognitive impairment predictions.
  3. Tertiary Objective: To compare the performance of Random Forest (RF), Support Vector Machine (SVM), and CatBoost (CB) classifiers in predicting MMSE scores using oral health data.

Study Type

Observational

Enrollment (Actual)

693

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Karlskrona, Sweden, 37179
        • Blekinge Institute of Technology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Data collected from the European collaborative study Support Monitoring and Reminder Technology for Mild Dementia (SMART4MD) and the Swedish National Study on Aging and Care (SNAC-B) will be analyzed. Participants aged 60 years or older will be included in the analysis.

Description

Inclusion Criteria:

  • Individuals aged 60 years or older.
  • Participants with recorded oral health parameters and MMSE scores of either 30 or ≤26.

Exclusion Criteria:

  • Individuals with MMSE scores of 27, 28, or 29, as these scores represent a transition phase between normal cognition and cognitive impairment, which could introduce variability.
  • Individuals younger than 60 years.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
MMSE ≤26
339 participants
A dataset comprising participants with MMSE scores of ≤26 and 30 will be used to evaluate the classification performance of various machine learning techniques.
Other Names:
  • MMSE 30
MMSE 30
354 participants
A dataset comprising participants with MMSE scores of ≤26 and 30 will be used to evaluate the classification performance of various machine learning techniques.
Other Names:
  • MMSE 30

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Detection perfomance
Time Frame: 5 mounths
The study measures the classification performance of Machine Learning classifiers. Performance metrics, Accuracy, precision, recall, F1-Score and confusion matrix will be used for the evaluation. The examination of the most important features relied on SHAP summary plots, providing visualizations of the influence of parameter groups on the output, organized by their importance. This importance is based on SHAP values, offering insights into features' effects on the ML model's decision-making process
5 mounths

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 10, 2024

Primary Completion (Actual)

October 10, 2024

Study Completion (Actual)

November 10, 2024

Study Registration Dates

First Submitted

September 17, 2024

First Submitted That Met QC Criteria

September 20, 2024

First Posted (Actual)

September 25, 2024

Study Record Updates

Last Update Posted (Estimated)

November 25, 2024

Last Update Submitted That Met QC Criteria

November 22, 2024

Last Verified

September 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Participant data can not be shared due to the GDPR.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cognitive Impairment

Clinical Trials on MMSE ≤26

Subscribe